The agreement was developed as a contingency plan to allow Israel`s Teva to sell generic lipitor or calcium atorvastatin if Ranbaxy`s version was not approved by the U.S. Food and Drug Administration before Lipitor lost its patent protection on November 30, 2011. The company entered into a settlement agreement with the U.S. Food and Drug Administration in 2011. However, the Public Prosecutor`s Office stated that it had not found, during its investigation, any anti-competitive effects on the basis of the agreement. While ranbaxy in India, majority-owned by Japanese company Daiichi Sankyo Co Ltd, finally got FDA clearance in due course, the deal was maintained and could have been used to protect other drugs from both companies. Indian generic drug maker Ranbaxy Laboratories Ltd pleaded guilty Monday to a charge of drug safety-related crimes and will pay $500 million in civil and criminal fines as part of the settlement agreement with the U.S. Department of Justice. Shares of both companies rose after agreeing to each pay $150,000 to The State of New York and waive similar agreements in the transaction in the future. The companies have neither acknowledged nor denied these allegations. (Reuters) – New York`s attorney general and the U.S.
units of Ranbaxy Laboratories Ltd and Teva Pharmaceutical Industries Ltd have made allegations that a deal between the two drugmakers illegally limited competition. Schneiderman said the case was the latest application of the recent precedent resulting from challenging “Pay for Delay” agreements between brand and generic manufacturers. “The financial provision made by Ranbaxy in December 2011 will be sufficient to cover all critical financial liabilities under the agreement,” the company said in a press release announcing the conclusion of the U.S. investigation. “Ranbaxy. still believes the deal has been pro-competitive and has been an important part of making the product available in a timely manner to patients and the U.S. healthcare system,” a Ranbaxy spokesperson said in an email to Reuters. . . .